Triazenes pp 145-159 | Cite as

Antitumour Imidazotetrazinones: Prodrugs Targeted to the Major Groove of DNA

  • Malcolm F. G. Stevens

Abstract

Triazene chemistry is full of surprises and this is the fourth chapter on the subject by the present author. The first review1 concentrated on detailing the biologically-relevant chemistry of monoalkyltriazenes; the second2 focused on the antitumour drug DTIC (1) and speculated that knowledge of the properties of this compound might be a springboard to improved agents; the third chronicled the background to the discovery of the imidazotetrazinones3 and summarised details of the spectacular pre-clinical biological activities of mitozolomide (formerly azolastone) (2) and the reasons behind the selection of temozolomide (3) as a second-generation agent.

Keywords

Hydroxamic Acid Major Groove Cancer Treatment Report Guanine Residue Carbamic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    K. Vaughan and M.F.G. Stevens, Chem. Soc. Review, 7, 377 (1978).CrossRefGoogle Scholar
  2. 2.
    M.F.G. Stevens, DTIC: a springboard to new antitumour agents, in: “Structure-Activity Relationships of Anti-Tumour Agents, D.N. Reinhoudt, T.A. Connors, H.M. Pinedo, and K.W. Van de Poll, eds., Martinus Nijboff, The Hague, pp. 183–218 (1983).CrossRefGoogle Scholar
  3. 3.
    M.F.G. Stevens, Second-generation azolotetrazinones, in: “New Avenues in Developmental Cancer Chemotherapy”, Academic Press, London, pp. 335–354 (1987).Google Scholar
  4. 4.
    M.F.G. Stevens, J. Chem. Soc., Perkin Trans. I, 1221 (1972).CrossRefGoogle Scholar
  5. 5.
    E.J. Gray and M.F.G. Stevens, J. Chem. Soc., Perkin Trans. I, 1492 (1976).CrossRefGoogle Scholar
  6. 6.
    E.J. Gray, M.F.G. Stevens, G. Tennant, and R.J.S. Vevers, J. Chem. Soc., Perkin Trans. I, 1496 (1976).CrossRefGoogle Scholar
  7. 7.
    E.J. Gray, H.N.E. Stevens, and M.F.G. Stevens, J. Chem. Soc., Perkin Trans. I, 885 (1978).CrossRefGoogle Scholar
  8. 8.
    G.U. Baig and M.F.G. Stevens, J. Chem. Soc., Perkin Trans I, 1424 (1981).CrossRefGoogle Scholar
  9. 9.
    G.U. Baig, M.F.G. Stevens, R. Stone, and E. Lunt, J Chem. Soc., Perkin Trans. I, 1811 (1982).CrossRefGoogle Scholar
  10. 10.
    S.P. Langdon, R.J. Simmonds, and M.F.G. Stevens, J Chem, Soc., Perkin Trans. I, 993 (1984).CrossRefGoogle Scholar
  11. 11.
    M.F.G. Stevens, Progr. in Medicin. Chem., 13, 205 (1979).CrossRefGoogle Scholar
  12. 12.
    G. Ege and K. Gilbert, Tetrahedron Lett., 4253 (1979).Google Scholar
  13. 13.
    M.F.G. Stevens, J.A. Hickman, R. Stone, N.W. Gibson, G.U. Baig, E. Lunt, and C.G. Newton, J Medicin. Chem., 27, 196 (1984).CrossRefGoogle Scholar
  14. 14.
    G.U. Baig, M.F.G. Stevens, E. Lunt, C.G. Newton, B.L. Pedgrift, C. Smith, C.G. Straw, R.J.A. Walsh, and P.J. Warren, U.K. Patent Application, 2,125,402A (1984).Google Scholar
  15. 15.
    J.A. Hickman, M.F.G. Stevens, N.W. Gibson, S.P. Langdon, C. Fizames, F. Lavelle, G. Atassi, E. Lunt, and R.M. Tilson, Cancer Res., 45, 3008 (1985).PubMedGoogle Scholar
  16. 16.
    M.F.G. Stevens, J.A. Hickman, S.P. Langdon, D. Chubb, L. Vickers, R Stone, G.U. Baig, C. Goddard, N.W. Gibson, J.A. Slack, C.G. Newton, E. Lunt, C. Fizames, and F. Lavelle, Cancer Res., 47, 5846 (1987).PubMedGoogle Scholar
  17. 17.
    E. Lunt, C.G. Newton, C. Smith, G.P. Stevens, M.F.G. Stevens, C.G. Straw, R.J.A. Walsh, P.J. Warren, C. Fizames, F. Lavelle, S.P. Langdon, and L.M. Vickers, J. Medicin. Chem., 30, 357 (1987).CrossRefGoogle Scholar
  18. 18.
    K.R. Horspool, M.F.G. Stevens, C.G. Newton, E. Lunt, R.J.A. Walsh, B.L. Pedgrift, G.U. Baig, F. Lavelle, and C. Fizames, J Medicin. Chem., in press.Google Scholar
  19. 19.
    G.U. Baig and M.F.G. Stevens, J. Chem. Soc., Perkin Trans I, 665 (1987).Google Scholar
  20. 20.
    J.A Slack and C. Goddard, J Chromatog., 337, 178 (1985).CrossRefGoogle Scholar
  21. 21.
    P.R. Lowe, C.H. Schwalbe, C.D. Whiston, and M.F.G. Stevens, J. Pharm. Pharmacol., 37, 136P (1985).Google Scholar
  22. 22.
    A.S. Clark, M.F.G. Stevens, C.E. Sansom, and C.H. Schwalbe, Anti-Cancer Drug Design, in press.Google Scholar
  23. 23.
    M.J. Tisdale, Biochem. Pharmacol., 34, 2077 (1985).PubMedCrossRefGoogle Scholar
  24. 24.
    M.J. Tisdale, Biochem. Pharmacol., 38, 1097 (1989).PubMedCrossRefGoogle Scholar
  25. 25.
    K.R. Horspool, C.P. Quarterman, J.A. Slack, A. Gescher, M.F.G. Stevens, and E. Lunt, Cancer Res., 49, 5023 (1989).PubMedGoogle Scholar
  26. 26.
    C.C. Cheng, E.F. Elslager, L.M. Werbel, S.R. Priebe, and W.R. Leopold, J. Medicin. Chem., 29, 1544 (1986).CrossRefGoogle Scholar
  27. 27.
    J.A. Hartley, N.W. Gibson, K.W. Kohn, and W.B. Mattes, Cancer Res., 46, 1943 (1986)PubMedGoogle Scholar
  28. 28.
    N.W. Gibson, J.A. Hartley, D. Barnes, and L.C. Erickson, Cancer Res., 46, 4995 (1986).PubMedGoogle Scholar
  29. 29.
    A. Gescher, J.A. Hickman, R.J. Simmonds, M.F.G. Stevens, and K. Vaughan, Tetrahedron Letters, 5041 (1978).Google Scholar
  30. 30.
    J.A. Double and M.C. Bibby, J. Nat. Cancer Inst., 81, 988 (1989).PubMedCrossRefGoogle Scholar
  31. 31.
    E.S. Newland, G. Blackledge, J.A. Slack, C Goddard, C.J. Brindley, L. Holden, and M.F.G. Stevens, Cancer Treatment Reports, 69, 801 (1985).Google Scholar
  32. 32.
    R.A. Joss, H.J. Ryssel, A.K. Bischoff, A. Goldhirsch, and K.W. Brunner, Cancer Treatment Reports, 70, 797(1986).Google Scholar
  33. 33.
    M. Harding, D. Northcott, J. Smyth, N.S.A. Stuart, J.A. Green, and E.S. Newlands, Br. J. Cancer, 57, 113 (1988).PubMedCrossRefGoogle Scholar
  34. 34.
    M. Harding, V. Docherty, R. Mackie, A. Dorward, and S. Kaye, Eur. J Cancer Clin. Oncol., 25, 785 (1989).PubMedCrossRefGoogle Scholar
  35. 35.
    P.R. Lowe, C.H. Schwalbe, and M.F.G. Stevens, J. Chem. Soc., Perkin Trans II, 357 (1985).Google Scholar
  36. 36.
    K.R. Horspool, Ph.D. Thesis, Aston University (1988).Google Scholar
  37. 37.
    R.S. McElhinney, Eur. J. Cancer Clin. Oncol., in press.Google Scholar
  38. 38.
    N. Buckley and T.P. Brent, J. Amer. Chem. Soc., 10, 7520 (1988).CrossRefGoogle Scholar
  39. 39.
    D.J. Dykes, W.R. Waud, S.D. Harrison, W.R. Laster, D.P. Griswold, Y.F. Shealy, and J.A. Montgomery, Cancer Res., 49, 1182 (1989)PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Malcolm F. G. Stevens
    • 1
  1. 1.Pharmaceutical Sciences Institute Department of Pharmaceutical SciencesAston UniversityBirminghamUK

Personalised recommendations